4/A: Sana Biotechnology Director Joshua H. Bilenker Corrects Option Shares Acquisition in Amended SEC Filing
SEC Filing
Joshua H. Bilenker, a director at Sana Biotechnology, files an amended Form 4/A to correct the number of option shares acquired on June 6, 2024.
Summary
- This is an amended Form 4/A filing by Joshua H. Bilenker, a director at Sana Biotechnology, Inc.
- The original filing contained a clerical error regarding the number of option shares acquired.
- The corrected filing reports the acquisition of 65,000 stock options on June 6, 2024, at an exercise price of $7.36.
- These options vest and become exercisable on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of Sana's stockholders, contingent upon continuous service to Sana through that date.
- Following the reported transaction, Bilenker beneficially owns 65,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a clerical error, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of the corrected transaction: acquisition of 65,000 stock options. |
| 06/07/2024 | Date of original filing that contained the error. |
| 06/06/2025 | Earliest date the options vest and become exercisable. |
| 07/15/2024 | Date of the amended filing (Form 4/A). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.